BioXcel Therapeutics Inc
NASDAQ:BTAI

Watchlist Manager
BioXcel Therapeutics Inc Logo
BioXcel Therapeutics Inc
NASDAQ:BTAI
Watchlist
Price: 1.88 USD 0.53% Market Closed
Market Cap: 41.1m USD

Net Margin
BioXcel Therapeutics Inc

-9 070.6%
Current
-19 887%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-9 070.6%
=
Net Income
-68.2m
/
Revenue
752k

Net Margin Across Competitors

No Stocks Found

BioXcel Therapeutics Inc
Glance View

Market Cap
37.6m USD
Industry
Biotechnology

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 89 full-time employees. The company went IPO on 2018-03-08. The company is focused on utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Its two advanced clinical development programs are BXCL501, which is an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, which is an investigational orally administered systemic innate immune activator for the treatment of castration resistant prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. The company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) for metastatic castration-resistant prostate cancer (mCRPC), in patients with adenocarcinoma and in patients with the aggressive variant small-cell neuroendocrine carcinoma.

BTAI Intrinsic Value
12.7 USD
Undervaluation 85%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-9 070.6%
=
Net Income
-68.2m
/
Revenue
752k
What is the Net Margin of BioXcel Therapeutics Inc?

Based on BioXcel Therapeutics Inc's most recent financial statements, the company has Net Margin of -9 070.6%.

Back to Top